Loading clinical trials...
Loading clinical trials...
To demonstrate that import Mesalazine (Asacol®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients with active ulcerative...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Tillotts Pharma AG
Collaborators
NCT05739864 · Active Ulcerative Colitis
NCT07232576 · Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06681389 · Healthy Adult Volunteers, Active Ulcerative Colitis, and more
NCT06589986 · Moderately to Severely Active Ulcerative Colitis
NCT03235752 · Active Ulcerative Colitis
Shanghai Hospital
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions